Samsung Pharm
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamin… Read more
Samsung Pharm (001360) - Total Liabilities
Latest total liabilities as of September 2025: ₩44.04 Billion KRW
Based on the latest financial reports, Samsung Pharm (001360) has total liabilities worth ₩44.04 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Samsung Pharm - Total Liabilities Trend (2012–2024)
This chart illustrates how Samsung Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Samsung Pharm Competitors by Total Liabilities
The table below lists competitors of Samsung Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bamboo Capital JSC
VN:BCG
|
Vietnam | ₫25.13 Trillion |
|
Identiv Inc
NASDAQ:INVE
|
USA | $7.36 Million |
|
Compagnie du Cambodge
PA:CBDG
|
France | €104.90 Million |
|
Nicolas Correa SA
MC:NEA
|
Spain | €57.54 Million |
|
Komelon Corporation
KQ:049430
|
Korea | ₩5.60 Billion |
|
Formosa Pharmaceuticals, Inc.
TW:6838
|
Taiwan | NT$595.70 Million |
|
Bharat Rasayan Limited
NSE:BHARATRAS
|
India | ₹2.59 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Samsung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Samsung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Samsung Pharm (2012–2024)
The table below shows the annual total liabilities of Samsung Pharm from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩22.60 Billion | +42.17% |
| 2023-12-31 | ₩15.89 Billion | +3.72% |
| 2022-12-31 | ₩15.32 Billion | -15.73% |
| 2021-12-31 | ₩18.19 Billion | -67.99% |
| 2020-12-31 | ₩56.81 Billion | +121.03% |
| 2019-12-31 | ₩25.70 Billion | -11.32% |
| 2018-12-31 | ₩28.98 Billion | -51.95% |
| 2017-12-31 | ₩60.33 Billion | +7.90% |
| 2016-12-31 | ₩55.91 Billion | -33.43% |
| 2015-12-31 | ₩83.98 Billion | +146.17% |
| 2014-12-31 | ₩34.12 Billion | -50.05% |
| 2012-12-31 | ₩68.31 Billion | -- |